Shamim Ruff - Jun 8, 2022 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role
Director
Signature
/s/ Tracy Herson, attorney-in-fact
Stock symbol
RETA
Transactions as of
Jun 8, 2022
Transactions value $
$219,941
Form type
4
Date filed
6/9/2022, 04:47 PM
Previous filing
Jan 5, 2022
Next filing
Mar 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Award $42.5K +1.22K +1035.59% $34.76 1.34K Jun 8, 2022 Direct F1, F2
transaction RETA Class A common stock Award $135K +3.88K +289.78% $34.76 5.22K Jun 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Stock Option (right-to-buy) Award $42.5K +1.77K $24.02 1.77K Jun 8, 2022 Class A common stock 1.77K $34.76 Direct F3, F4
transaction RETA Stock Option (right-to-buy) Award $0 +5.62K $0.00 5.62K Jun 8, 2022 Class A common stock 5.62K $34.76 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares represent Restricted Stock Units (RSU), which vest in four equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through the vesting date.
F2 These RSUs were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $42,500.00.
F3 The options vest in four equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through the vesting date.
F4 These options were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $42,500.00.